Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database.
about
A systematic review of worldwide epidemiology of psoriasis.Interactions of the Immune System with Skin and Bone Tissue in Psoriatic Arthritis: A Comprehensive Review.Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)Cutting Edge: PD-1 Regulates Imiquimod-Induced Psoriasiform Dermatitis through Inhibition of IL-17A Expression by Innate γδ-Low T Cells.Association between Psoriasis Vulgaris and Coronary Heart Disease in a Hospital-Based Population in Japan.Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study.Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: Results of SALSA study.Economic burden of psoriatic patients in Japan: Analysis from a single outpatient clinic.What do we know about palmoplantar pustulosis?Mutation analysis of IL36RN gene in Japanese patients with palmoplantar pustulosis.Hyperuricemia is an independent risk factor for psoriatic arthritis in psoriatic patients.Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial.Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1).Epidemiology and cardiovascular comorbidities in patients with psoriasis: A Korean nationwide population-based cohort study.Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.Prevalence of Psoriasis in Korea: A Population-Based Epidemiological Study Using the Korean National Health Insurance Database.Analysis of treatment goal alignment between Japanese psoriasis patients and their paired treating physicians.Epidemiological survey from 2009 to 2012 of psoriatic patients in Japanese Society for Psoriasis Research.Serum C-reactive protein levels in Japanese patients with psoriasis and psoriatic arthritis: Long-term differential effects of biologics.Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan.Clinical characteristics of Japanese patients with psoriatic arthritis: Comparison with East Asian countries.Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study.PD-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skin.Epidemiological survey of patients with psoriasis in Matsumoto city, Nagano Prefecture, Japan.Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups.Biologic treatments for elderly patients with psoriasis.[Initially undetected de novo psoriasis triggered by nivolumab for metastatic base of the tongue carcinoma].Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial.UVA1 vs. narrowband UVB phototherapy in the treatment of palmoplantar pustulosis: a pilot randomized controlled study.Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis.Serum interleukin-6 levels in response to biologic treatment in patients with psoriasis.Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.Human Leukocyte Antigen-Class I Alleles and the Autoreactive T Cell Response in Psoriasis Pathogenesis.Association of high psychiatrist staffing with prolonged hospitalization, follow-up visits, and readmission in acute psychiatric units: a retrospective cohort study using a nationwide claims database.Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database.Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled studyHypertension and risk of psoriasis incidence: An 11-year nationwide population-based cohort study
P2860
Q30248242-2695937D-027F-4DDD-82C4-C7D2D5B8E32DQ30251957-64EAA2D3-535E-4D5F-99FE-5DD85855E0DBQ33626095-1918628A-8A6D-4877-A87B-B3737AF68021Q35815759-A07AF205-A25F-4A5A-B0D0-BE8A76A35F3BQ35934076-93AF8434-FE6C-426D-9475-4CD175FD745DQ37345488-82C15174-BEAC-4822-8D95-B3BD90220268Q37412858-F5ABDC28-8985-496F-8FF1-1DAAE48B1C2EQ38838614-D4E305EF-037B-48FB-96FA-F8BC1BDE6263Q38926801-951530C5-2435-42CE-866A-E9B1007A7FC9Q39472493-F1FDE384-99FD-49E1-8712-B83B47AB05C4Q40129865-1E8192B5-4A87-4530-99EC-1E91BB7EDE95Q40132474-BA49239B-E430-44C8-BD43-0DFC37E93A89Q40164166-8554D127-5CBA-4679-9D8E-3E4313C7E8AEQ40338652-0AEB530C-DABB-456F-BB2D-26D47E75BA48Q41540546-6678C93A-2E4E-4F5F-88B4-E07C2936EFA4Q47100186-EA5FFEC6-8161-4502-B22B-C22DA975FAD5Q47242645-161E25BC-238E-4799-9F74-8F89FA48FB24Q47586451-62D1FBC2-1048-4406-9ABF-E5619210778DQ47930789-C52F6A58-5B15-4E82-B4D6-FFF7A6A8C73FQ48023865-6823FA71-9EA5-4752-8202-F91B1F734B23Q48144520-10C695E6-F232-432A-9419-C07EB070A7E9Q48148751-8C349CEE-18A7-41C7-8E99-DFAE370A6802Q48162560-5D6A4798-0472-4F6F-9110-881CD16BADA7Q48163947-99898F2A-411D-4A5E-AE0E-C1A6689C93E0Q48170767-944381DF-E782-46B9-9337-5B2D1D18F8D1Q48236525-3BE02CC2-EF53-4C6E-B1EC-50F0077FE368Q50058093-92A43AAC-F5D8-4BD7-87BA-A46E309E91B6Q50126864-E1A271A9-0247-45A3-970D-C7252B1ACBA9Q50247726-83DCF945-A55B-462B-9203-C2325EBE12DFQ51435941-A565734E-6B75-4A5E-9F53-E88E07B91062Q53089186-B70BB96E-CA7B-403E-A49B-670204E6F98BQ53835593-6A7F9C73-9707-4F92-A469-81E53ABAF9E8Q54917709-37D68B34-F163-4972-AD4F-7E4B7B1DB99EQ54981634-97B32445-BF79-4EA1-B9D3-5075B9B3FC3EQ55652012-91BC345B-4F03-417C-8268-BD30502AAF75Q57705930-F8189E10-1F09-4690-AE98-CAAA8BB60C6CQ58708700-36F3A6EC-D2DA-493C-9CFC-9DC781F3B925
P2860
Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Epidemiology of psoriasis and ...... nese national claims database.
@ast
Epidemiology of psoriasis and ...... nese national claims database.
@en
Epidemiology of psoriasis and ...... nese national claims database.
@nl
type
label
Epidemiology of psoriasis and ...... nese national claims database.
@ast
Epidemiology of psoriasis and ...... nese national claims database.
@en
Epidemiology of psoriasis and ...... nese national claims database.
@nl
prefLabel
Epidemiology of psoriasis and ...... nese national claims database.
@ast
Epidemiology of psoriasis and ...... nese national claims database.
@en
Epidemiology of psoriasis and ...... nese national claims database.
@nl
P2093
P2860
P1433
P1476
Epidemiology of psoriasis and ...... nese national claims database.
@en
P2093
Daisuke Koide
Hajime Iizuka
Hidemi Nakagawa
Nobuhiro Ooba
Tsugumichi Sato
Yukari Kamijima
P2860
P304
P356
10.1136/BMJOPEN-2014-006450
P577
2015-01-14T00:00:00Z